Literature DB >> 3873119

Protamine-induced thrombocytopenia and leukopenia.

H Al-Mondhiry, W S Pierce, R M Basarab.   

Abstract

Protamine has been reported to cause thrombocytopenia and granulocytopenia. In this article, we report studies examining the relative contribution of protamine and heparin in the pathogenesis of this phenomenon, the dose-effect relationship, and the possible mechanism of cell loss. Protamine alone infused into experimental animals causes mild, transient granulocytopenia and thrombocytopenia. The sequential administration of heparin and protamine results in a more severe cytopenia lasting 30 to over 60 min. Organ scanning with 111In-labeled platelets shows a striking though transient accumulation of radioactivity in the lungs following heparin-protamine infusion. Platelet survival, however, is not shortened. Incubation of 125I-labeled protamine with blood cells in the presence of heparin results in tight binding of the drug to platelets and granulocytes. These observations suggest that protamine and heparin form a complex that binds to blood cells. The sequestration of coated cells in the lungs results in transient granulocytopenia and thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873119

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Protamine-induced immune thrombocytopenia.

Authors:  Atul Singla; Mia J Sullivan; Grace Lee; John Bartholomew; Samir Kapadia; Richard H Aster; Brian R Curtis
Journal:  Transfusion       Date:  2013-02-05       Impact factor: 3.157

2.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

3.  The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents.

Authors:  Joanna Miklosz; Bartlomiej Kalaska; Kamil Kaminski; Malgorzata Rusak; Krzysztof Szczubialka; Maria Nowakowska; Dariusz Pawlak; Andrzej Mogielnicki
Journal:  Mar Drugs       Date:  2019-09-17       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.